Allspring Global Investments Holdings LLC Decreases Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Allspring Global Investments Holdings LLC decreased its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 31.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,287 shares of the biopharmaceutical company’s stock after selling 1,044 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Ultragenyx Pharmaceutical were worth $127,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. Headlands Technologies LLC purchased a new position in shares of Ultragenyx Pharmaceutical in the first quarter worth $28,000. nVerses Capital LLC purchased a new position in Ultragenyx Pharmaceutical during the 2nd quarter valued at $33,000. UMB Bank n.a. grew its position in shares of Ultragenyx Pharmaceutical by 58.1% in the 2nd quarter. UMB Bank n.a. now owns 958 shares of the biopharmaceutical company’s stock worth $39,000 after buying an additional 352 shares during the period. Lazard Asset Management LLC grew its position in shares of Ultragenyx Pharmaceutical by 140.9% in the 1st quarter. Lazard Asset Management LLC now owns 4,160 shares of the biopharmaceutical company’s stock worth $193,000 after buying an additional 2,433 shares during the period. Finally, Capstone Investment Advisors LLC bought a new position in Ultragenyx Pharmaceutical in the 1st quarter worth about $227,000. 97.67% of the stock is currently owned by institutional investors.

Ultragenyx Pharmaceutical Trading Up 0.1 %

NASDAQ:RARE opened at $51.06 on Tuesday. Ultragenyx Pharmaceutical Inc. has a twelve month low of $34.06 and a twelve month high of $60.37. The company has a market cap of $4.71 billion, a price-to-earnings ratio of -6.99 and a beta of 0.58. The stock has a fifty day simple moving average of $55.58 and a 200-day simple moving average of $48.02.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on RARE shares. TD Cowen upped their target price on shares of Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the company a “buy” rating in a research note on Monday, October 21st. Barclays reduced their target price on shares of Ultragenyx Pharmaceutical from $83.00 to $81.00 and set an “overweight” rating for the company in a report on Monday, August 5th. Wedbush increased their target price on shares of Ultragenyx Pharmaceutical from $43.00 to $46.00 and gave the stock a “neutral” rating in a report on Friday, August 2nd. Royal Bank of Canada reaffirmed an “outperform” rating and set a $77.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Thursday, September 26th. Finally, Wells Fargo & Company increased their target price on Ultragenyx Pharmaceutical from $72.00 to $75.00 and gave the company an “overweight” rating in a research report on Friday, August 2nd. Two investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Ultragenyx Pharmaceutical currently has an average rating of “Moderate Buy” and an average target price of $85.17.

Insider Transactions at Ultragenyx Pharmaceutical

In other news, CFO Howard Horn sold 7,465 shares of Ultragenyx Pharmaceutical stock in a transaction on Thursday, October 10th. The stock was sold at an average price of $52.76, for a total transaction of $393,853.40. Following the completion of the sale, the chief financial officer now directly owns 92,301 shares in the company, valued at approximately $4,869,800.76. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 7,465 shares of Ultragenyx Pharmaceutical stock in a transaction dated Thursday, October 10th. The stock was sold at an average price of $52.76, for a total value of $393,853.40. Following the transaction, the chief financial officer now owns 92,301 shares in the company, valued at $4,869,800.76. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Emil D. Kakkis sold 20,000 shares of Ultragenyx Pharmaceutical stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $55.85, for a total value of $1,117,000.00. Following the completion of the transaction, the chief executive officer now owns 2,223,985 shares in the company, valued at $124,209,562.25. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 27,556 shares of company stock worth $1,515,967. 5.80% of the stock is currently owned by insiders.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.